Diagnosis and Management of Type 1 Diabetes

Interpretation of C-Peptide Level

The American Diabetes Association (ADA) classification algorithm for adults with diabetes states that a C-peptide level <200 pmol/L (<0.6 ng/mL) definitively indicates type 1 diabetes 1, 2, 3
A C-peptide level of 0.31 ng/mL (approximately 103 pmol/L) falls well below the 200 pmol/L threshold that distinguishes type 1 from type 2 diabetes, according to the ADA guidelines 1, 2, 3
The ADA flowchart confirms that C-peptide values <200 pmol/L indicate type 1 diabetes, while values >600 pmol/L (>1.8 ng/mL) indicate type 2 diabetes 1, 2, 3

The ADA guidelines acknowledge that type 1 diabetes can present at any age, including in adults over 35 years, and that late-onset type 1 diabetes accounts for a significant proportion of adult-onset type 1 diabetes 1, 2
In adults over 35 years with autoantibody-negative diabetes, the ADA recommends making clinical decisions based on C-peptide levels and clinical features 1, 2, 3
Type 2 diabetes should be considered in older individuals, but a severely low C-peptide level overrides age as a diagnostic factor 2, 3

This patient will require insulin therapy for survival due to the severely depleted C-peptide, which indicates absolute insulin deficiency 1, 2, 3

Islet autoantibody testing (GAD, IA-2, ZnT8) should still be performed to confirm autoimmune etiology, though 5-10% of type 1 diabetes patients are antibody-negative 1, 2, 3
If autoantibodies are negative and there are features suggesting monogenic diabetes, genetic testing should be considered 1, 2, 3
C-peptide should not be measured within 2 weeks of a hyperglycemic emergency (DKA), as this can temporarily suppress values 1, 2, 3

This patient requires immediate insulin therapy as the primary treatment modality 1, 2, 3
Non-insulin therapies (oral agents) are inappropriate for type 1 diabetes with this degree of beta-cell failure 1, 2, 3